Somewhat Favorable Media Coverage Somewhat Unlikely to Impact AxoGen (AXGN) Share Price

News coverage about AxoGen (NASDAQ:AXGN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AxoGen earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 45.2659201817039 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

AxoGen (AXGN) opened at $27.30 on Thursday. The stock has a market capitalization of $954.63, a price-to-earnings ratio of -65.00 and a beta of 0.89. AxoGen has a fifty-two week low of $8.75 and a fifty-two week high of $31.70. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $16.05 million during the quarter, compared to analyst estimates of $15.55 million. AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. AxoGen’s revenue for the quarter was up 43.2% on a year-over-year basis. research analysts anticipate that AxoGen will post -0.31 EPS for the current year.

Several research analysts have recently commented on the company. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Leerink Swann restated an “outperform” rating and set a $23.00 price target (up from $22.00) on shares of AxoGen in a research report on Saturday, September 30th. Lake Street Capital raised their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 21st. Wedbush restated a “buy” rating and set a $27.00 price target (up from $22.00) on shares of AxoGen in a research report on Tuesday, November 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AxoGen in a research report on Friday, January 5th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $29.33.

In related news, Director Guido J. Neels sold 1,150,000 shares of AxoGen stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.74, for a total value of $22,701,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jamie Mark Grooms sold 84,295 shares of AxoGen stock in a transaction on Friday, December 8th. The shares were sold at an average price of $26.38, for a total value of $2,223,702.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,293,990 shares of company stock valued at $26,494,898. 9.33% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-axogen-axgn-share-price.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply